- Details
- Description
TRAMEDX (Trametinib) is a pharmaceutical product containing trametinib, a targeted anticancer medicine that acts as a MEK1 and MEK2 inhibitor. Trametinib works by blocking specific signaling pathways involved in the growth and proliferation of cancer cells.
Trametinib is used in the treatment of certain cancers, including specific cases of unresectable or metastatic melanoma with a BRAF V600 mutation, and may be used in combination with other targeted therapies according to approved indications. Treatment selection depends on the cancer type, molecular characteristics, patient condition, and applicable clinical guidelines.
TRAMEDX is intended for oral administration and should be used under the supervision of a qualified healthcare professional. The appropriate dosage, treatment duration, combination therapy, monitoring, and management of potential adverse reactions should be determined by the treating physician.
Product strength, packaging, manufacturer, availability, and regulatory status may vary depending on the market and specific product presentation. Patients and healthcare professionals should consult the official product information before use.
